Researchers at the University of Manchester are looking to collaborate with the pharmaceutical industry to validate their model of hPS-CM as a standard model of screening for cardiotoxicity.
Partners are sought to help develop and validate this novel spontaneous object recognition apparatus that allows reduced variability in spontaneous recognition tasks.
Partners are sought to supply new chemical entities with corresponding animal/ human data on nausea and/or vomiting, to validate a novel screen using Dictyostelium.
Kirkstall Ltd is looking for partners to help develop their Quasi-Vivo® system (multiple cell types can be cultured in inter-connected chambers) for studies of drug and chemical toxicity, disease, DMPK and stem cell differentiation.
Toxicologists and pharmaceutical developers are sought to validate and further develop VEGA, a QSAR model to predict compound toxicity.
FibromEd Ltd have developed HepatoinformTM, an iPSC derived platform for assessing hepatotoxicity.
Collaboration is sought with the pharmaceutical or biotechnology sector to develop and validate primary cell cultures for inter-species comparisons of renal toxicity between toxicologically relevant species and man.
KIYATEC Inc is seeking collaborators from the pharmaceutical or biotechnology sector for co-development of novel 3D cell-based assays and models.
Brainwave-Discovery Ltd is looking to collaborate with a pharmaceutical company to develop and validate new models of neurodegenerative disease for target validation and compound screening.